Can Scotts Miracle-Gro Prove Its Commodity Hedges Actually Worked?

Scotts Miracle-Gro Company (SMG) reports fiscal second-quarter earnings on April 29, 2026, before market open, with analysts expecting the lawn and garden products maker to deliver $3.97 per share on revenue estimates near $1.4 billion. The central question: can SMG sustain the momentum from its recent earnings beats and translate improving technical signals into fundamental outperformance as the critical spring selling season unfolds? With the stock trading at $65.38 and analysts projecting 14% full-year EPS growth, this report will test whether the company's turnaround narrative can withstand heightened expectations.

Part 1: Earnings Preview

Scotts Miracle-Gro Company manufactures and markets branded consumer lawn and garden products across North America, including fertilizers, grass seed, pest control solutions, and hydroponic growing systems under names like Scotts®, Miracle-Gro®, and Ortho®. The company serves both retail consumers and professional landscapers through a diversified portfolio spanning traditional outdoor gardening and specialty indoor growing categories.

SMG is scheduled to report fiscal Q2 2026 results on April 29, 2026, before market open. Analysts expect $3.97 per share, slightly below the $3.98 reported in the same quarter last year, representing a modest -0.25% year-over-year decline. The most recent quarter (Q1 FY2026, reported January 28, 2026) delivered -$0.77 per share, beating estimates by nearly 26%. For the full fiscal year ending September 2026, the consensus stands at $4.27, implying 14.17% growth versus the prior year's $3.74.

Three key themes define this earnings story:

Spring Season Execution: The fiscal second quarter captures the heart of the spring selling season—the most critical period for lawn and garden retailers. Investors will scrutinize whether SMG capitalized on favorable weather patterns and consumer demand trends, particularly after management's April guidance update set FY2026 EPS at $4.15–$4.35, roughly in line with consensus. Any deviation from seasonal norms or retail inventory dynamics could significantly impact full-year projections.

Margin Recovery and Cost Management: With the company emerging from a multi-year restructuring, analysts are focused on whether operating leverage is materializing as expected. Recent analyst commentary highlights concerns about input cost pressures and promotional intensity in the retail channel, making gross margin performance a key metric. The company's ability to balance volume growth with pricing discipline will signal whether the turnaround is gaining sustainable traction.

Hawthorne Segment Stabilization: SMG's hydroponic and specialty growing business (Hawthorne) has been a persistent headwind, but recent quarters suggest the segment may be finding a bottom. Analysts are watching for signs of sequential improvement or further deterioration in this higher-margin category, which has outsized influence on overall profitability despite representing a smaller revenue share.

Analyst commentary ahead of the release reflects cautious optimism. JPMorgan downgraded SMG from Overweight to Neutral in late March, cutting its price target from $70 to $67, citing concerns about valuation following the stock's rally and uncertainty around spring season sell-through. Conversely, Stifel Nicolaus raised its target from $70 to $79 in early March, maintaining a Buy rating and pointing to improving fundamentals and better-than-expected cost control. Wells Fargo recently trimmed its target from $75 to $72 but kept an Overweight rating, noting that while near-term execution risks remain, the risk/reward profile favors patient investors. The consensus view suggests analysts are waiting for concrete evidence that the spring season is delivering as planned before committing to more aggressive bullish stances.

Part 2: Historical Earnings Performance

Scotts Miracle-Gro has demonstrated a pattern of beating earnings estimates in three of the last four quarters, with surprises ranging from modest to substantial. The most recent quarter (December 2025) delivered a +25.96% beat, reporting -$0.77 versus the -$1.04 estimate—a significant outperformance during the seasonally weak winter period. The prior quarter (September 2025) saw a minor -4.26% miss at -$1.96 versus -$1.88 expected, the only disappointment in the recent sequence.

The standout performance came in June 2025, when SMG posted $2.59 against a $2.19 estimate, delivering an +18.26% surprise during the peak spring selling season. March 2025 showed a more modest +0.76% beat at $3.98 versus $3.95 expected. This pattern suggests the company has improved its ability to manage expectations and execute during critical seasonal windows, particularly in the spring and summer quarters when lawn and garden demand peaks.

The trend indicates improving operational consistency after what appears to have been a challenging prior period. The magnitude of recent beats—particularly the 26% and 18% surprises—suggests either conservative guidance from management or genuine operational momentum exceeding internal forecasts. However, the September miss serves as a reminder that execution risks remain, especially during transitional quarters. Heading into the April 29 report, the -0.25% year-over-year decline in the consensus estimate (versus the strong $3.98 delivered last year) may reflect analyst caution rather than fundamental deterioration, potentially setting up another positive surprise if spring season trends prove favorable.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Scotts Miracle-Gro typically reports before market open, meaning Day 0 captures the first full trading session where investors react to results, while Day +1 reflects follow-through momentum or reversal.

Historical price behavior reveals significant volatility around SMG earnings releases, with an average absolute Day 0 move of 7.07% and an average intraday range of 11.07%—well above typical single-day volatility for the stock. The Day +1 follow-through averages 2.41% with a 4.82% range, indicating that initial reactions often moderate but meaningful secondary moves are common.

The most extreme reaction came in November 2024, when the stock plunged -20.52% on Day 0 following disappointing results, demonstrating the downside risk when SMG misses expectations during a critical quarter. Conversely, the July 2024 report triggered an +11.90% Day 0 surge, showing the upside potential when the company delivers positive surprises during peak season. More recent reports have shown more moderate reactions: January 2026 saw a -0.68% Day 0 move followed by a +4.17% Day +1 rally, while November 2025 posted +2.86% initially with minimal follow-through.

The pattern suggests investors should expect a meaningful initial move—likely in the 5–8% range based on recent history—with the direction heavily dependent on whether results and guidance exceed, meet, or fall short of expectations. The substantial Day 0 ranges (often exceeding 10%) indicate active intraday trading and potential opportunities for volatility-oriented strategies. The relatively smaller Day +1 moves suggest the market typically digests the news quickly, though the January 2026 example shows that delayed reactions can occur when initial interpretations prove incomplete.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.88% expected move through the May 15 expiration (17 days out), which sits below the 7.07% average historical Day 0 move but within the range of recent earnings reactions. This suggests options traders are anticipating moderate volatility—less dramatic than the extreme moves seen in 2024 but still meaningful. The implied move appears reasonably calibrated to recent history, offering neither obvious value nor excessive premium for volatility buyers.

Part 3: What Analysts Are Saying

Analysts maintain a Buy consensus on Scotts Miracle-Gro with an average rating of 4.00 (on a 5-point scale where 5 is Strong Buy) and a mean price target of $73.40—implying 12.3% upside from the current $65.38 price. The rating distribution shows 4 Strong Buy ratings and 4 Hold ratings among the 8 analysts covering the stock, with no Sell or Strong Sell recommendations. This balanced split reflects a market where bulls see meaningful appreciation potential while more cautious analysts prefer to wait for further proof of execution.

The price target range spans $67.00 to $82.00, with the high estimate suggesting 25% upside for optimistic scenarios and the low estimate implying just 2.5% upside—a relatively tight band that indicates analysts have converged on a similar fundamental view despite rating differences. The $73.40 mean target sits comfortably above current levels, supporting the notion that the risk/reward profile favors patient holders if the company can deliver on its turnaround thesis.

Analyst sentiment has remained unchanged over the past month, with the rating count and average recommendation holding steady at 4.00. This stability follows a period of more active revision activity in February and March, when JPMorgan's downgrade and Stifel's upgrade created offsetting moves. The current stasis suggests analysts are in wait-and-see mode ahead of the April 29 report, preferring to let the spring season results speak before making further commitment changes. The lack of recent downgrades despite the stock's rally from the low-$60s to mid-$60s indicates analysts believe current valuation remains reasonable relative to the improving fundamental outlook, though the absence of upgrades suggests conviction remains measured until execution is proven.

Part 4: Technical Picture

Scotts Miracle-Gro enters earnings with strengthening technical momentum, as the Barchart Technical Opinion has surged to an 80% Buy signal—a dramatic improvement from the 56% Buy reading just one week ago and a complete reversal from the 8% Sell signal registered one month ago. This rapid shift reflects improving price action and technical indicator alignment as the stock has consolidated recent gains.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not yet at extreme levels, suggesting room for further upside if earnings catalyze additional buying
• Medium-term (100% Buy): Strong buy signal across all medium-term indicators reflects solid intermediate-term trend strength and suggests the recent rally has established a sustainable uptrend structure
• Long-term (100% Buy): Unanimous long-term buy signal indicates the broader trend has decisively turned positive, providing a supportive backdrop for investors with multi-quarter time horizons

Trend Characteristics: The combination of Average strength and Average direction suggests the stock is in a healthy but not overextended uptrend—positive momentum is present without the warning signs of exhaustion that often accompany parabolic moves, creating a balanced technical environment heading into the earnings event.

The stock is trading at $65.38, positioned above its 10-day ($65.04), 20-day ($63.70), 50-day ($65.05), 100-day ($62.96), and 200-day ($61.18) moving averages but below its 5-day moving average ($65.69). This configuration indicates broad-based trend support across all major timeframes, with the minor pullback below the 5-day average representing normal short-term consolidation rather than trend deterioration.

Key technical levels to watch include the $65.05 fifty-day moving average, which has provided support on recent tests and now sits just below current prices, and the recent high near $72.35 established in early April, which represents the next upside target if earnings drive a breakout. The stock's position above all major long-term moving averages provides a cushion against downside volatility, while the recent consolidation has created a technically sound base for a potential post-earnings rally. Overall, the technical setup is supportive heading into earnings, with improving momentum indicators, strong trend structure, and no obvious signs of overextension that would suggest elevated risk of a negative reaction even on in-line results.